JPRN-jRCT2080223074未知3 期
A Multicenter, Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg compared with Leuprorelin in the Treatment of Uterine Fibroids
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 288
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •Inclusion Criteria for Entering the Screening (at VISIT 1)
- •1. In the opinion of the investigator or subinvestigator, the participant is capable of understanding and complying with protocol requirements.
- •2. The participant signs and dates a written, informed consent form prior to the initiation of any study procedures.
- •3. Prior to VISIT 1, the participant has a diagnosis of uterine fibroids confirmed by transvaginal ultrasound, abdominal ultrasound, magnetic resonance imaging (MRI), computed tomography (CT), or laparoscopy, and has never received surgical treatment for the myoma (measurable noncalcified myoma with a longest diameter of >= 3 cm).
- •4. The participant is a premenopausal Japanese woman.
- •5. The participant is aged 20 years or older on the day of signing and dating the informed consent form.
- •6. The participant has 1 or more measurable noncalcified myomas with a longest diameter of >= 3 cm confirmed by transvaginal ultrasound.
- •7. The participant has experienced 1 or more regular menstrual cycles (25 to 38 days) immediately prior to VISIT 1 and that should include menstrual bleeding of at least 3 consecutive days.
- •8. The participant who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study.
- •Inclusion Criteria for Entering the Run-in (at VISIT 2)
- •9. The participant has experienced regular menstrual cycles (25 to 38 days) immediately prior to VISIT 2 that should include menstrual bleeding of at least 3 consecutive days (at least 2 regular menstruation cycles to be confirmed by Inclusion criteria #7 and #9).
- •Inclusion Criteria for Entering the Treatment (at VISIT 3)
- •10. The participant has 1 or more measurable noncalcified myomas, with a longest diameter of >= 3 cm confirmed by transvaginal ultrasound (the same myoma should be measured as in Inclusion criterion #6).
- •11. The participant has a diagnosis of menorrhagia with a total PBAC score of >= 120 in 1 menstrual cycle just before VISIT 3.
- •12. The participant has experienced regular menstrual cycles (25 to 38 days) after VISIT 1 that should include menstrual bleeding of at least 3 consecutive days (at least 3 regular menstruation cycles to be confirmed by Inclusion criteria #7, #9 and #12).
排除标准
- •1. The participant has received any investigational compound within 24 weeks prior to the start of the administration of the study medication for the Run-in (VISIT 2).
- •2. The participant has received TAK-385 (including placebo) in a previous clinical study.
- •3. The participant is an immediate family member, study site employee, or is in a dependant relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
- •4. The participant has a previous or current history of blood disorders (eg, thalassemia, sickle cells anemia, folic-acid deficiency, and coagulopathy), excluding (latent) iron-deficiency anemia.
- •5. The participant has a known history of severe hypersensitivity or severe allergy to sanitary goods.
- •6. The participant has lower abdominal pain due to irritable bowel syndrome or severe interstitial cystitis.
- •7. The participant has a current history of thyroid gland disorder with irregular menstruation, or has a potential for irregular menstruation due to thyroid gland disorder, as determined by the investigator or subinvestigator.
- •8. The participant has a previous or current history of pelvic inflammatory disease within the 8 weeks prior to VISIT 1.
- •9. The participant has a positive Pap smear test result conducted within the 1 year prior to VISIT 1 (if there are no previous test results, those who were judged positive in the test conducted before VISIT 2).
- •10. The participant has a history of panhysterectomy or bilateral oophorectomy.
- •11. The participant has had markedly abnormal uterine bleeding or anovulatory bleeding, as determined by the investigator or subinvestigator.
- •12. The participant has a malignant tumor or a history of a malignant tumor within the 5 years prior to VISIT 1.
- •13. The participant has been treated with any of the following drugs (excluding drugs for external use and dietary supplements) within the 4 weeks prior to VISIT 2: anti-coagulant drugs, anti-platelet drugs, tranexamic acid, selective estrogen receptor modulators (SERMs), activated vitamin D preparations, other vitamin D preparations, calcitonin, ipriflavone, steroid hormones, vitamin K preparations, teriparatide, or denosumab.
- •14. The participant has been treated with any of the following drugs within the 8 weeks prior to VISIT 2: oral contraceptive or sex hormone preparations (norethindrone, norethisterone, medroxyprogesterone, estrogen, or other progestins), and within the 16 weeks prior to VISIT 2: gonadotropin-releasing hormone (GnRH) analogues, dienogest, danazol, or aromatase inhibitors (for 1- and 3-month sustained-release preparations, within the 20 and 28 weeks prior to VISIT 2, respectively).
- •15. The participant has been treated with a bisphosphonate preparation within the 24 weeks prior to VISIT 2.
- •16. The participant has a previous or current history of hypersensitivity or allergies to leuprorelin, synthetic GnRH, GnRH agonists or GnRH antagonists, or has a previous or current history of severe hypersensitivity or severe allergy to other drugs.
- •17. The participant has nondiagnosable abnormal genital bleeding.
- •18. Female participant who is pregnant, lactating, or intending to become pregnant or to donate ova prior to signing of informed consent, during the study period, or within 1 month after the end of the study.
- •19. The participant has a previous or current history of osteoporosis, osteopenia, or other metabolic bone diseases.
- •20. The participant has clinica
研究者
相似试验
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of 12 Week Treatment with Vildagliptin (LAF237) 50 mg QD in Subjects with Impaired Glucose Tolerance (IGT)Type II DiabetesEUCTR2005-002778-30-FIovartis Pharma Services AG
进行中（未招募）
1 期
A clinical trial of TEV-48125 to evaluate long term safety, tolerability and efficacy for the Preventive Treatment of MigraineEpisodic and Chronic MigraineMedDRA version: 20.0 Level: LLT Classification code 10066636 Term: Chronic migraine System Organ Class: 100000004852MedDRA version: 20.0 Level: LLT Classification code 10027602 Term: Migraine headache System Organ Class: 100000004852EUCTR2015-004550-18-FITeva Branded Pharmaceutical Products R&D, Inc.1,890
进行中（未招募）
不适用
A Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple SclerosisEUCTR2008-006333-27-EEBiogen Idec Limited1,500
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Crohn's DiseaseCrohn's DiseaseEUCTR2020-004775-40-LVArena Pharmaceuticals Inc.1,265
进行中（未招募）
1 期
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Patients Who Did Not Respond to Prior Preventive Migraine Treatmentsepisodic and chronic migraineMedDRA version: 20.0 Level: HLT Classification code 10027603 Term: Migraine headaches System Organ Class: 100000004852EUCTR2017-002441-30-BETeva Branded Pharmaceutical Products R&D, Inc.838